Kronos Bio Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 [Yahoo! Finance]
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.
Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $6.00.